Key Drivers
- Strong Liquidity
- Persistent Cash Burn
- Share Dilution
AIAI Summary
ANNX is now a high-risk late-stage execution bet: tanruprubart's Q4 2026 BLA and vonaprument's pivotal durability data could unlock major value, but sustained cash burn and prior dilution mean investors should demand regulatory-quality evidence and monitor runway discipline rather than value platform potential alone.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Persistent Cash Burn
- •Share Dilution
ANNX has ample liquidity and low debt, but persistent losses, negative cash flow, dilution, and a high book-value multiple make it a speculative, financing-dependent investment.
Price Behavior
Key Price Behavior Insights:
- •Downtrend persists
- •Support rebound
- •Oversold momentum
ANNX fell 18% over the last month but is rebounding from $3.92 support; watch for a break below $3.92 or sustained strength above $4.67.
Rebounded from a 21-session low of $3.92 to $4.23
Sentiment & News
Key News Insights:
- •Investor conferences
- •Employee inducements
- •No catalysts
Annexon advanced investor outreach and employee hiring via inducement equity grants, with no new clinical, regulatory, or financial updates.
The announcements are operationally neutral and unlikely to materially affect Annexon's near-term valuation
Similar Companies in Healthcare
Other companies in the same sector with AI ratings